Arcus Biosciences RCUS Business Segments — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's business segments — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's business segments — D&A?
- Arcus Biosciences (RCUS) reported business segments — D&A of $2M in Q1 2026.
- How has Arcus Biosciences's business segments — D&A changed year-over-year?
- Arcus Biosciences's business segments — D&A decreased by 33.3% year-over-year, from $3M to $2M.
- What is the long-term trend for Arcus Biosciences's business segments — D&A?
- Over 3 years (2022 to 2025), Arcus Biosciences's business segments — D&A has grown at a 18.6% compound annual growth rate (CAGR), from $6M to $10M.
- What does business segments — D&A mean?
- Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the segment. This metric helps in understanding the capital intensity of the segment's infrastructure and intellectual property portfolio.